Consent given pursuant to Sections 14 and 14A to the importation and supply of therapeutic goods specified - Stallergenes Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods, including medicines, medical devices, and blood products, ensuring they are safe, of high quality, and effective. This legislation was introduced to address the need for a comprehensive regulatory framework governing the import, supply, and manufacture of therapeutic goods within Australia. Enacted by the Australian Parliament, the Act aims to protect public health by setting stringent standards and processes for therapeutic goods, including the requirement for approval before therapeutic goods can be supplied in Australia. This legislative framework ensures that therapeutic goods available to consumers and healthcare professionals meet necessary safety and quality benchmarks. The Therapeutic Goods Act 1989, through provisions such as Section 14 and 14A, allows the Secretary of the Department of Health to grant specific consents for the importation and supply of therapeutic goods that do not fully comply with certain standards, as was the case with ALBUMIN-SALINE diluent [AUST R 32486]. The policy objective behind such consents is to balance public health protection with the availability of therapeutic goods that might otherwise be restricted, thereby facilitating access to potentially beneficial treatments under controlled conditions.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, encompassing medicines, medical devices, blood, tissues, and related products within Australia. This legislation governs the importation, manufacture, supply, and advertising of these goods, ensuring they meet quality, safety, and efficacy standards. The Act applies to individuals, companies, and other entities involved in any stage of the therapeutic goods lifecycle, as well as to the conduct and transactions associated with these goods. Geographically, the Act has a national reach, applying across the Commonwealth of Australia, including states and territories, to ensure uniform regulation and oversight of therapeutic goods. Certain goods, such as over-the-counter medicines and certain low-risk medical devices, may be exempt from some requirements under the Act, provided they meet specified criteria. The application of the Act can be extended or restricted through subordinate instruments, which provide detailed regulations and standards that must be adhered to for different types of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") provides mechanisms for regulating the importation, supply, and use of therapeutic goods in Australia. Sections 14 and 14A of the Act are particularly significant as they allow for the granting of consents for the importation and supply of therapeutic goods that do not fully comply with certain standards. In this case, Section 14(1) allows the delegate of the Secretary of the Department of Health to consent to the importation and supply of therapeutic goods that do not meet specific regulatory requirements if certain conditions are satisfied. Section 14A outlines the procedure for such consents, including the ability to impose conditions to mitigate any risks associated with the non-compliance of these goods. Under Section 14, the delegate has the authority to issue consents based on an application from a party, such as Stallergenes Australia Pty Ltd, which in this instance applied for consent to import and supply ALBUMIN-SALINE diluent [AUST R 32486] that does not conform to specific standards outlined in Clause 9(3) and (4)/Table(f) of the Therapeutic Goods Order No. 88. This consent allows the specified product to be imported and supplied, despite it not meeting the donor selection, testing, and infectious disease transmission requirements for human blood and blood components, human tissues, and human cellular therapy products. The obligations imposed by the Act on entities like Stallergenes Australia Pty Ltd include the submission of a detailed application to the delegate, which must include information justifying why the therapeutic goods should be exempted from certain regulatory requirements. The delegate, upon reviewing the application, must consider whether the consent can be granted without compromising public health and safety. If consent is granted, conditions may be attached to the consent to ensure any potential risks are managed effectively. Stallergenes Australia Pty Ltd, in this instance, must adhere to any such conditions stipulated in the consent. Failure to comply with the conditions of the consent, or any other requirements set out in the Act, can lead to significant consequences. The Act provides for both civil and criminal penalties for breaches. Civil penalties can include fines up to a significant amount, depending on the nature and severity of the breach. Criminal penalties may also apply, with potential fines and imprisonment for individuals found guilty of contravening the Act. It is essential for entities to carefully adhere to the terms of any consent granted under Sections 14 and 14A to avoid these penalties.